DYNAMIC BIOREACTOR MODEL TO MIMIC EARLY CARDIAC FIBROSIS IN DIABETES.

Area of Science:

• Cardiovascular Biology
• Cellular and Molecular Medicine
• Biomaterials and Tissue Engineering

Background:

• Diabetic cardiomyopathy involves hyperglycemia-induced cardiac fibroblast activation and fibrosis.
• Understanding fibroblast behavior is crucial for developing antifibrotic therapies.

Purpose of the Study:

• To establish an optimal in vitro model simulating high glucose effects on human cardiac fibroblasts.
• To investigate the roles of transforming growth factor-beta (TGF-β) and nitric oxide in fibrosis.
• To evaluate 2D, 3D, and tissue-engineered models for mimicking diabetic cardiomyopathy.

Main Methods:

• Cultured human cardiac fibroblasts in 2D, 3D, and tissue-engineered myocardial matrix scaffolds.
• Utilized a bioreactor system delivering biochemical (high glucose, TGF-β) and mechanical stimuli.
• Assessed fibroblast activation and collagen deposition.

Main Results:

• High glucose concentrations demonstrated potent pro-fibrotic effects on cardiac fibroblasts.
• Combined high glucose and TGF-β significantly amplified fibroblast activation.
• The tissue-engineered model using decellularized myocardial scaffolds in a bioreactor proved effective.

Conclusions:

• A bioreactor-based tissue engineering platform accurately models early-stage fibrotic processes in diabetic cardiomyopathy.
• This model serves as a valuable tool for screening antifibrotic agents.
• High glucose and TGF-β are key drivers of cardiac fibrosis in this context.